Colorectal cancer treatment resistance : mechanisms, insights, advances and solutions /
Colorectal Cancer Treatment Resistance: Mechanisms, Insights, Advances and Solutions provide insights, knowledge, and potential solutions for healthcare professionals, researchers, and individuals affected by colorectal cancer.
| Corporate Author: | |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
London, United Kingdom :
Academic Press,
2025.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Front Cover
- Colorectal Cancer Treatment Resistance
- Copyright Page
- Contents
- List of contributors
- Preface
- Part 1: Understanding Colorectal Cancer Drug Resistance
- Part 2: Innovative Approaches to Overcoming Drug Resistance
- Part 3: Molecular Factors and Therapeutic Strategies
- Part 4: Future Perspectives and Advanced Research
- 1 Understanding colorectal cancer drug resistance
- 1 Unraveling the mystery of treatment resistance in colorectal cancer
- Abbreviations
- Introduction
- Drug resistance in colorectal cancer
- Future technologies in overcoming treatment resistance
- Overcoming treatment resistance
- Chemotherapy resistance
- Immunotherapy and immunomodulation in treatment resistance
- Targeting alternative splicing
- Nanomedicine
- ncRNA in reversing resistance in colorectal cancer
- Targeting genetic signatures in overcoming colorectal cancer resistance
- Surgical interventions
- Research advances in colorectal treatment resistance
- Microbes in colon cancer drug resistance
- Conclusion
- Conflicts of interest
- References
- 2 Mechanisms of treatment resistance in colorectal cancer
- Abbreviations
- Introduction
- Multifaceted mechanisms underlying treatment resistance
- Role of pharmacokinetics in the evolution of treatment resistance
- Increased drug excretion
- Drug target alteration
- DNA damage repair
- The role of tumor microenvironment stromal cells in the evolution of treatment-resistant colorectal cancer
- Mesenchymal stem cells
- Cancer-associated fibroblasts
- Immunosuppressive cells
- The role of adipocytes
- Why do certain therapies fail?
- Potential targets for intervention to overcome resistance
- Limitations
- Conclusion
- Conflict of interest
- References
- 3 Biomarkers and predictive factors in colorectal cancer treatment resistance
- Abbreviations.
- Introduction
- Biomarkers in colorectal cancer diagnosis, prognosis, therapy, and response
- Diagnostic biomarkers in colorectal cancer
- Prognostic biomarkers in colorectal cancer
- Predictive biomarkers in colorectal cancer
- Predictive factors in colorectal cancer treatment resistance
- Hypermethylation
- Tumor microenvironment
- Other factors
- Colorectal cancer exposome and disparities
- Effects of ecosystems on colorectal cancer
- Lifestyles factors and colorectal cancer
- Social variables and colorectal cancer
- Advances and integrated approaches in colorectal cancer prognostic biomarker discovery
- Genomics
- Proteomics
- Metabolomics
- Multiomics approaches
- Challenges and limitations
- Conclusions
- Conflict of interest
- References
- 4 Targeted therapies and precision medicine in colorectal cancer drug resistance
- List of abbreviations
- Introduction
- Innovative approaches that tailor treatments to the unique genetic and molecular characteristics
- Ground-breaking advances in precision medicine and FDA-accepted targeted therapies
- Bevacizumab
- Cetuximab
- Panitumumab
- Ziv-Aflibercept
- Regorafenib
- Ramucirumab
- Pembrolizumab
- Nivolumab
- Ipilimumab
- Encorafenib
- Molecular pathways of colorectal cancer and potential targeted therapies
- Rat sarcoma-mutation targeted therapy
- Serine/threonine-protein kinase B-Raf mutation targeted therapy
- Microsatellite Instability targeted therapy
- Neurotrophic tyrosine receptor kinase gene fusion targeted therapy
- The role of phytochemical-based targeted therapy in colorectal cancer
- Combination therapy measures
- Limitations
- Conclusion
- Conflicts of interest
- References
- 2 Innovative approaches to overcoming drug resistance
- 5 Overcoming chemotherapy resistance in colorectal cancer
- Abbreviations.
- Introduction into colorectal cancer
- Strategies to overcome chemotherapy resistance in colorectal cancer
- Medications and supplements
- Metformin
- Ivermectin
- Dichloroacetate
- Bazedoxifene
- Enalapril
- Melatonin
- Vitamins
- S-adenosylmethionine
- Nonsteroidal antiinflammatory drugs
- Gene therapy
- Ribozymes
- RNA interference
- Antisense oligonucleotides
- Clustered regularly interspaced short palindromic repeats
- Epigenetic therapy
- Noncoding RNAs
- Protein inhibitors
- Inhibitors of common resistance-related proteins
- Epidermal growth factor receptor inhibitors
- Sphingosine 1 phosphate receptor modulators
- Natural herbal compounds
- Innovative drug delivery system
- Liposomes
- Hydrogels
- Nanocarriers
- Exosomes
- Combinational therapy
- Supportive care measures
- Limitations
- Conclusion
- Conflict of Interest
- References
- 6 Emerging treatment approaches for colorectal cancer treatment resistance
- Abbreviations
- Introduction
- Targeted therapies
- Epidermal growth factor receptor inhibitors
- Antiangiogenic agents
- Human epidermal growth factor receptor 2-targeted therapies
- BRAF inhibitors
- Mismatch repair and microsatellite instability targeting
- PI3K/AKT/mTOR pathway inhibitors
- Wnt pathway inhibitors
- Human epidermal growth factor receptor 3-targeted therapies
- Immunotherapies
- Immune checkpoint inhibitors and the MSI-H/dMMR subset
- Expanding immunotherapy to microsatellite stable colorectal cancer
- Personalized vaccines and neoantigen targeting
- Chimeric antigen receptor T-cell therapy
- Bispecific antibodies and T-cell engagers
- Microbiome modulation and response to immunotherapy
- Combination therapies
- Personalized medicine strategies
- Limitations and outlook
- Conclusion
- Conflict of Interest
- References.
- 7 Immunotherapy and immunomodulation in colorectal cancer treatment resistance
- Abbreviations
- Introduction
- Current immunotherapeutic strategies in metastatic colorectal cancer management
- Understanding immunotherapy resistance mechanisms in colorectal cancer
- Immunotherapy strategies for overcoming treatment resistance
- Overcoming resistance mechanisms
- Ten-eleven translocation 1
- Ring-finger protein 43
- Nuclear receptor coactivator 3
- Large tumor suppressor
- Neurogenic locus notch homolog protein 3
- Cyclic-AMP response element binding protein
- Remodeling the tumor microenvironment
- Combinational therapies and efforts to tailor therapy for individualized treatment
- Challenges and limitations
- Future directions and perspectives
- Opportunities in implementing innovative approaches and optimizing therapeutic outcomes
- Reshaping the landscape of colorectal cancer management
- Conclusion
- Conflict of Interest
- References
- 8 Splicing-associated drug resistance in colorectal cancer: targeting splicing signatures
- Abbreviations
- Introduction
- Alternate splicing events in colon cancer
- Cis regulatory elements
- Transregulatory factors in colorectal cancer
- Posttranslational alterations of transregulatory splicing factors
- Alternative splicing in drug resistance in colorectal cancer
- DNA damage response
- Resistance to apoptosis
- Invasion and metastasis
- Altering angiogenesis
- Targeting alternative splicing to reverse drug resistance
- Antisense oligonucleotides
- Therapeutic approaches of small molecule inhibitors
- Conclusion
- Conflict of Interest
- References
- 9 Nanomedicine innovations: conquering colorectal cancer drug resistance
- Introduction
- Mechanisms of drug resistance in colorectal cancer
- Mechanism of action of nanoparticles.